Dyne Therapeutics, Inc.

Developing TfR1-targeted oligonucleotide conjugates for serious muscle diseases. Zeleciment rostudirsen is in the Phase 3 FORZETTO trial, with a U.S. accelerated-approval BLA planned.

Back to company catalog

Rare neuromuscular disease · Targeted oligonucleotide conjugates · Phase 3 / BLA planned

Compare report options